Ignite Creation Date:
2024-05-06 @ 12:14 AM
Last Modification Date:
2024-10-26 @ 10:46 AM
Study NCT ID:
NCT01522469
Status:
COMPLETED
Last Update Posted:
2024-01-30
First Post:
2012-01-30
Brief Title:
Phase II Study of Crenolanib in Subjects With RelapsedRefractory AML With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals Inc
Organization:
Arog Pharmaceuticals Inc
Organization Data
Organization:
Arog Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
ARO-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Arog Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None